Nathanael S. Gray
Co-Founder & Member of Scientific Advisory BoardDr. Nathanael S. Gray, Ph.D., serves as Member of Scientific Advisory Board at Red Tree Venture Capital. He is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery, Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). He is Member of Scientific Advisory Board of Inception Sciences, Inc. Dr. Gray is Co-Founder, Member of Scientific Advisory Board and Board Member of Larkspur Biosciences Inc. He is a Co-founder and Board Member of Soltego, Inc. He is the Founder of Matchpoint Therapeutics, Inc. Dr. Gray has been a Member of Scientific Advisory Board at Aduro BioTech, Inc. since April 2019. Dr. Gray is the Founder of C4 Therapeutics, Inc. Dr. Gray co-founded Petra Pharma Corporation in 2016 and has been its Chairman of Scientific Advisory Board and Member of Scientific Advisory Board since July 27, 2017. Dr. Gray is the Scientific Founder of Syros Pharmaceuticals, Inc. Dr. Gray serves as an Assistant Professor in the Department of Cancer Biology at the Dana Farber Cancer Research Institute with a joint appointment in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His research utilizes tools of synthetic chemistry, protein biochemistry and cancer biology to discover and validate new strategies for the inhibition of anticancer targets. Dr. Gray’s research has had a broad impact on the areas of kinase inhibitor design and in circumventing drug resistance. He was Co-founder of Syros Pharmaceuticals, Inc. Prior to joining the faculty at Harvard Medical School, Dr. Gray served as The Director of Biological Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF). He was Group Leader at Novartis. He is Principal Investigator of Dana-Farber Cancer Institute, Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School. He has been Member of Scientific Advisory Board at C4 Therapeutics, Inc. since November 17, 2016. He has been a Member of Scientific Advisory Board at Syros Pharmaceuticals, Inc since April 2013. He served as a Member of Advisory Board of The Assay Depot Inc., since September 2008. In 2006, Dr. Gray accepted a faculty appointment at the Dana-Farber Cancer Institute at Harvard Medical School. There, he established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as the human epidermal receptor (HER3) and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s research laboratory also developed the first T790M mutation-selective EGFR tyrosine kinase inhibitors; ATP-competitive inhibitors of mammalian target of rapamycin (mTor); Torin1 and went on to discover that rapamycin is an incomplete inhibitor of mTOR; and the first inhibitors of extracellular-signal-regulated kinase 5 (ERK5), also known as big MAP kinase 1 (BMK1); cyclin-dependent kinase (CDK) 7; and CDK12. These contributions have been recognized through numerous awards including the American Chemical Society Award for Biological Chemistry in 2011, American Association for Cancer Research Team Science Award in 2010, Damon Runyon-Rachleff Innovation Award in 2008, National Science Foundation CAREER and Oustanding Achievement awards in 2007 and 2011, respectively. Dr. Gray received his PhD in Organic Chemistry from the University of California, Berkeley in 1999 after receiving his bachelor’s degree with the highest honor award from there in 1995. During his PhD work, Dr. Gray developed new combinatorial chemistry and functional genomics approaches that resulted in the discovery of purvalanol, one of the first selective inhibitors of cyclin-dependent kinases.
Positions
- Company NameC4 Therapeutics, Inc.Stock CodeCCCCPositionCo-Founder & Member of Scientific Advisory BoardColleagues
- AJAndrew J. HirschCEO, President & Director
- RHRonald H. W. CooperIndependent Chairman
- KCKenneth C. AndersonCo-Founder, Independent Director & Member of Scientific Advisory Board
- KRKendra R. AdamsPrincipal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer
- LMLeonard M. J. ReynoChief Medical Officer
- UKUtpal KoppikarIndependent Director
- Company NameSyros Pharmaceuticals, Inc.Stock CodeSYRSPositionScientific Founder & Member of Scientific Advisory BoardColleagues
- JEJames E. BradnerFounder
- NSNathanael S. GrayScientific Founder & Member of Scientific Advisory Board
- MFMatthew FosterChief Restructuring Officer
- BEBradley E. BernsteinMember of Scientific Advisory Board
- SAScott A. BillerMember of Scientific Advisory Board
- GEGerard EvanMember of Scientific Advisory Board
- SKStefan KnappMember of Scientific Advisory Board
